|1.||Germain, Pierre: 2 articles (09/2007 - 12/2004)|
|2.||Kammerer, Sabrina: 2 articles (09/2007 - 12/2004)|
|3.||Gronemeyer, Hinrich: 2 articles (09/2007 - 12/2004)|
|4.||Lamph, William W: 2 articles (03/2006 - 05/2002)|
|5.||Brown, Powel H: 2 articles (03/2006 - 05/2002)|
|6.||Wu, Kendall: 2 articles (03/2006 - 05/2002)|
|7.||Nishi, Y: 2 articles (12/2001 - 08/2000)|
|8.||Yanase, T: 2 articles (12/2001 - 08/2000)|
|9.||Mu, Y M: 2 articles (12/2001 - 08/2000)|
|10.||Takayanagi, R: 2 articles (12/2001 - 08/2000)|
|2.||Breast Neoplasms (Breast Cancer)
11/21/2011 - "4-Hydroxybenzyl modification of the highly teratogenic retinoid, 4-[(1E)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-propen-1-yl]benzoic acid (TTNPB), yields a compound that induces apoptosis in breast cancer cells and shows reduced teratogenicity."
09/01/1998 - "The present study aims to characterize the effect which four retinoids (TTNPB, 9-cis-RA, LGD 1069, 4-HPR) with distinct RAR/RXR binding properties induced on various in vitro and in vivo mouse and human breast cancer models. "
01/01/1986 - "The ability of all-trans-retinoic acid, 13-cis-retinoic acid, the free acid of etretinate (RO 10-1670), the 'arotinoid' RO 13-6298 and its free acid RO 13-7410 to affect the growth of T47D human breast cancer cells in vitro was investigated. "
08/30/2000 - "In the present study, we investigated the effects of a nuclear receptor system constituted by retinoid X receptor (RXR) and its heterodimer partner on the aromatase activity in a cultured MCF-7 human breast cancer cell line, using each selective ligand for retinoic acid receptor (RAR) (TTNPB), RXR (LG100268), PPARgamma (troglitazone), and vitamin D(3) receptor (vitamin D(3)). "
12/01/2001 - "We investigated the effects of a nuclear receptor system constituted by retinoid X receptor (RXR) and its heterodimer partner on the aromatase activity in a cultured MCF-7 human breast cancer cell line and also in human ovarian granulosa cells, using each selective ligand for retinoic acid receptor, RAR (TTNPB), retinoid X receptor, RXR (LG100268), PPARgamma (troglitazone), and vitamin D3 receptor (cholecalciferol). "
|3.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
05/01/2002 - "TTNPB-treated mice showed a delayed median time to tumor development (131 days for vehicle versus 154 days for 3.0 microg/kg TTNPB; P < or = 0.05), but no changes were seen in tumor multiplicity. "
11/21/2011 - "Unlike TTNPB, both compounds induce apoptosis in cancer cells and bind poorly to the retinoic acid receptors (RARs). "
03/01/2006 - "Work from our laboratory showed that an RXR-selective retinoid LGD1069 prevented tumor development in animal models of cancer with reduced toxicity as compared to an RAR-selective retinoid TTNPB. "
12/20/2004 - "In PLB985 leukemia cells that require RXR agonists for differentiation compounds 8 induced maturation in the presence of the RAR-selective pan-agonist TTNPB; this effect was blocked by an RXR-selective antagonist."
12/04/2000 - "We discovered that the cis-TTNPB 9c possesses apoptotic activity comparable with that of the retinoid 4. Moreover, the amino arotinoid 16c showed potent apoptotic activity in HL60 promyelocytic leukemia cells. "
09/24/2007 - "Like TTNPB (1 a) and 3-methyl-TTNPB (2 a), the analogous silicon-based arotinoids 1 b and 2 b are strong pan-RAR agonists and display the same strong differentiation and apoptosis-inducing activity in NB4 promyelocytic leukemia cells as the parent carbon compounds. "
|1.||Benzoic Acid (Ucephan)
|3.||ethyl- p- ((E)- 2- (5,6,7,8- tetrahydro- 5,5,8,8- tetramethyl- 2- naphthyl)- 1- propenyl)benzoic acid
|5.||Retinoic Acid Receptors (Retinoic Acid Receptor)
|6.||Retinoid X Receptors (Retinoid X Receptor)
|9.||Calcitriol Receptors (Calcitriol Receptor)